GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Sito Bio-technology Co Ltd (SZSE:300583) » Definitions » Cash Conversion Cycle

Shandong Sito Bio-technology Co (SZSE:300583) Cash Conversion Cycle : 205.21 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Shandong Sito Bio-technology Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Shandong Sito Bio-technology Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 79.49.
Shandong Sito Bio-technology Co's Days Inventory for the three months ended in Mar. 2025 was 230.46.
Shandong Sito Bio-technology Co's Days Payable for the three months ended in Mar. 2025 was 104.74.
Therefore, Shandong Sito Bio-technology Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2025 was 205.21.


Shandong Sito Bio-technology Co Cash Conversion Cycle Historical Data

The historical data trend for Shandong Sito Bio-technology Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Sito Bio-technology Co Cash Conversion Cycle Chart

Shandong Sito Bio-technology Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.32 83.71 102.87 191.91 278.13

Shandong Sito Bio-technology Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 339.49 232.73 369.52 246.06 205.21

Competitive Comparison of Shandong Sito Bio-technology Co's Cash Conversion Cycle

For the Biotechnology subindustry, Shandong Sito Bio-technology Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Sito Bio-technology Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Sito Bio-technology Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Shandong Sito Bio-technology Co's Cash Conversion Cycle falls into.


;
;

Shandong Sito Bio-technology Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Shandong Sito Bio-technology Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=89.04+317.96-128.87
=278.13

Shandong Sito Bio-technology Co's Cash Conversion Cycle for the quarter that ended in Mar. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=79.49+230.46-104.74
=205.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Sito Bio-technology Co  (SZSE:300583) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Shandong Sito Bio-technology Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Shandong Sito Bio-technology Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Sito Bio-technology Co Business Description

Traded in Other Exchanges
N/A
Address
South Section of East Outer Ring Road, Dingtao District, Shandong Province, Heze, CHN, 274100
Shandong Sito Bio-technology Co Ltd is a biotechnology company. It uses genetic engineering technology and microbial transformation technology to develop and produce steroid drug raw materials, specialty respiratory raw materials and finished preparations, and other drug intermediaries. The company operates in the following business segments; intermediates, high-end specialty respiratory APIs, and preparations. Its product offerings include androstenedione (AD), 9-hydroxy androstenedione (90H-AD), 17a-hydroxyprogesterone derivatives (A ring), and bi-decanoic acid (BA), and others. In addition, the company holds patents for various APIs and other intermediaries.
Executives
Mi Qi Directors, executives
Wang Min Director
Kong Qing Zhi Executives
He Jian Yong Directors, executives
Ceng Qing Li Securities Affairs Representative

Shandong Sito Bio-technology Co Headlines

No Headlines